Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01178 (
oxytocin
)
15,767
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Oxytocin
is an essential hormone for mammalian labor and lactation. Here, we show a new function of
oxytocin
in causing plastic changes in hippocampal synapses during motherhood. In
oxytocin
-perfused hippocampal slices, one-train tetanus stimulation induced long-lasting, long-term potentiation (L-LTP) and phosphorylation of cyclic AMP-responsive element binding protein (CREB), and
MAP kinase
inhibitors blocked these inductions. An increase in CREB phosphorylation and L-LTP induced by one-train tetanus were observed in the multiparous mouse hippocampus without
oxytocin
application. Furthermore, intracerebroventricular injection of
oxytocin
in virgin mice improved long-term spatial learning in vivo, whereas an injection of
oxytocin
antagonist in multiparous mice significantly inhibited the improved spatial memory, L-LTP and CREB phosphorylation. These findings indicate that
oxytocin
is critically involved in improving hippocampus-dependent learning and memory during motherhood in mice.
...
PMID:Oxytocin improves long-lasting spatial memory during motherhood through MAP kinase cascade. 1265 76
The mechanisms by which
oxytocin
(OT) stimulates extracellular signal-regulated kinase 1/2 (
ERK1
/2) are only partially understood. OT receptor (OTR) signals predominantly through Galpha(q), but
ERK1
/2 phosphorylation (
ERK1
/2-P) in PHM1 myometrial cells was not eliminated by inhibition of downstream effectors such as phospholipase C or protein kinase C. Inconsistent with a Galpha(i)-coupled response, pertussis toxin inhibition of OT-induced
ERK1
/2-P was reversed by the protein kinase A inhibitors Rp-cAMPS and KT5720. Consistent with an inhibitory role for protein kinase A, pertussis toxin pretreatment raised cellular cAMP and 8-(4-chlorophenylthio)-cAMP inhibited OT-induced
ERK1
/2-P. Attenuation of the OT response by the Gbetagamma scavenger carboxyl terminus of the beta-adrenergic receptor kinase implicated a Gbetagamma-mediated pathway. In both COSM6 cells overexpressing OTR (OTR-COSM6) and in PHM1 cells, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 markedly reduced OT-induced
ERK1
/2-P, whereas the platelet-derived growth factor receptor tyrosine kinase inhibitor AG1296 had no effect. Furthermore, OT increased EGFR tyrosine phosphorylation in OTR-COSM6 cells, which was inhibited by AG1478 or EGTA plus thapsigargin pretreatment. AG1478 did not affect inositol 1,4,5-triphosphate production by OT or protein kinase C-stimulated
ERK1
/2-P but completely blocked ionomycin-induced
ERK1
/2-P and EGFR tyrosine phosphorylation. In both OTR-COSM6 and PHM1 cells, EGTA reduced OT-stimulated
ERK1
/2-P; no
ERK1
/2-P was observed when intracellular calcium increases were blocked by pretreatment with thapsigargin plus EGTA. These data are consistent with activation of a Gbetagamma-mediated pathway as a consequence of Galpha(q) activation in myometrium and OTR-COSM6 cells that results in increased
ERK1
/2-P. This pathway involves both EGFR activation and an influence of calcium.
...
PMID:Extracellular signal-regulated kinase 1/2 activation by myometrial oxytocin receptor involves Galpha(q)Gbetagamma and epidermal growth factor receptor tyrosine kinase activation. 1281 May 50
Growth hormone (GH), prostaglandins F (PGF) and prostaglandins E (PGE) are important regulators of ovarian function. Therefore, interrelationships between GH and these substances and their intracellular mechanisms might be of physiological significance in the ovary. The aims of this study on cultured porcine ovarian granulosa cells were to determine the effect of GH on the secretion of
oxytocin
(OT), PGF and PGE and whether
MAP kinase
could be involved in the mediation of GH action. Experiments were carried out with cultured porcine granulosa cells to investigate the effects of exogenous pGH (1-100 ng/ml) on the expression of
MAP kinase
(ERK-1, -2) and of PGH (1-100 ng/ml) and the
MAP kinase
blocker PD 98059 (1 microg/ml) on the secretion of PGF, PGE and OT. The cellular content of ERK-1 and -2 was analyzed by Western immunoblotting and immunocytochemistry, whilst PGF, PGE and OT accumulation in the medium was measured by RIA. Addition of GH to culture medium significantly altered the pattern of ovarian ERK
MAP kinase
on SDS-PA gels: the 44 and 42 kDa bands were reduced and additional 50 and 48 kDa bands appeared. Moreover, there was an increase in the percentage of cells containing ERK
MAP kinase
. GH stimulated the secretion of PGF (at a concentration of 1 ng GH per ml medium) and OT (100 ng GH per ml), but not PGE. The
MAP kinase
blocker alone did not affect PGF, PGE and OT secretion but did prevent the stimulatory effects of GH on PGF and induced stimulatory action of GH (10 ng/ml) on PGE. GH-stimulated OT secretion was unaffected. These observations confirm the role of GH in regulating porcine ovarian PGF, PGE and OT secretion and the presence of ERK
MAP kinase
in porcine granulosa cells. Furthermore, our studies demonstrate that
MAP kinase
-dependent intracellular mechanisms are dependent on GH, and that these mechanisms are involved in the mediation of GH action on ovarian PGF and PGE but not OT secretion.
...
PMID:Involvement of MAP kinase in the mediation of GH action on ovarian granulosa cells. 1289 May 81
We have recently shown that
oxytocin
inhibits cell proliferation when the vast majority of
oxytocin
receptors are excluded from caveolin-1-enriched microdomains, and that, on the contrary, it has a mitogenic effect when the receptors are targeted to these plasma membrane domains. In this study, we investigated whether the receptors located inside and outside caveolar microdomains initiate different signalling pathways and how this may lead to opposite effects on cell proliferation. Our data indicate that, depending on their localization,
oxytocin
receptors transactivate EGFR and activate
ERK1
/2 using different signalling intermediates. The final outcome is a different temporal pattern of EGFR and
ERK1
/2 phosphorylation, which is more persistent when the receptors are located outside caveolar microdomains and inhibit cell growth, and very transient when they are located in caveolar microdomains and stimulate cell growth. Finally, only the activation of receptors located outside caveolar microdomains correlates with the activation of the cell cycle inhibitor p21(WAF1/CIP1), thus suggesting that the antiproliferative OTR effects may, in this case, be achieved by a sustained activation of EGFR and
MAPK
leading to the induction of this cell cycle regulator.
...
PMID:Oxytocin receptor elicits different EGFR/MAPK activation patterns depending on its localization in caveolin-1 enriched domains. 1295 84
The central melanocortin system has emerged as a potential regulator of food intake. This action of melanocortins appears to occur through intrahypothalamic, melanocortin-containing projections, including those from the arcuate to the paraventricular nucleus (PVN). Although the complexity of feeding behavior and the long duration of the effects of melanocortins on food intake suggest changes in gene expression, the mechanism by which such changes occur has been elusive. In the present report, we describe experiments using in vitro and in vivo approaches to demonstrate melanocortin-induced phosphorylation (activation) of members of the
mitogen-activated protein kinase
(
MAPK
) family of transcription factors. First, application of the melanocortin agonist MTII to COS-1 cells resulted in an increase in phosphorylated
MAPK
after the cells were transfected with the melanocortin type 4 receptor (MC4-R), but not the type 3 receptor. Formation of cAMP, however, was observed when either receptor subtype was transfected. Subsequent experiments revealed that the effect of MTII on
MAPK
activation in MC4-R-transfected cells was dose-dependent and was maximal after 10 min of MTII exposure. Second, central injections of MTII increased the number of phospho-
MAPK
-immunoreactive cells in the rat PVN compared to vehicle-injected animals. When coupled with immunohistochemical identification of PVN neurons containing
oxytocin
, a clear segregation was apparent, allowing for a precise anatomical description of the pattern of activated
MAPK
within the PVN. These data are the first to suggest a differential coupling of MC4-R and may describe a mechanism through which the long-term and persistent behavioral actions of melanocortins are mediated.
...
PMID:Melanocortin receptor signaling through mitogen-activated protein kinase in vitro and in rat hypothalamus. 1296 24
The aims of the present study were (1) to investigate the influence of insulin-like growth factor-I (IGF-I) on follicular size, on the secretion of
oxytocin
(OT), progesterone (P), estradiol (E), IGF binding protein-3 (IGFBP-3), inhibin A, inhibin B and cAMP and on the expression of proliferation-associated peptide PCNA, ERK-related mitogen activated protein kinase (
MAPK
/
ERK1
, 2) and protein kinase A (PKA) in cultured porcine ovarian follicles; (2) to examine the effects of OT on IGF-I and on these functions; and (3) to determine whether the effects of IGF-I can be mediated by OT. To define the involvement of OT in mediating IGF-I action, we compared responses of porcine ovarian follicles to IGF-I and OT and examined whether blockade of endogenous OT by specific antiserum can affect IGF-I action. It was observed that IGF-I (1, 10 or 100 ng/ml) was able to prevent a decrease in the size of ovarian follicles during culture and caused an increase in the diameter of some follicles. It also stimulated the secretion of OT, P, IGFBP-3, inhibin A and cAMP, decreased the secretion of E and inhibin B (RIA/EIA/ELISA), and induced the expression of PCNA, PKA,
MAPK
/
ERK1
, but not
MAPK
/
ERK2
(Western blotting). Like IGF-1, OT (100 ng/ml) prevented decrease in follicular size and increased the diameter of some follicles. It also stimulated the secretion of P and IGF-I, but not E. Antiserum against OT (1%), when given alone, did not affect the reduction of follicular size but slightly increased the percentage of follicles increasing their diameter during culture. The antiserum also inhibited secretion of OT and cAMP but not the secretion of P, E, IGFBP-3 or the expression of PKA,
MAPK
/
ERK1
or 2. When given together with IGF-I, the antiserum prevented the stimulatory action of IGF-I on the proportion of enlarged follicles and on OT, IGFBP-3 and
MAPK
/
ERK1
. It augmented the effect of IGF-I on P, but not the effect on E, cAMP, PKA or
MAPK
/
ERK2
. These observations demonstrate the involvement of IGF-I and OT in the control of ovarian follicular size and follicular cell proliferation, progestagen, estrogen, IGFBP-3, inhibin A and B secretion and in cAMP/PKA- and
MAPK
/
ERK1
-dependent intracellular mechanisms. Furthermore, the reciprocal stimulation of IGF-I and OT and the similarity of some their effects, together with the prevention or augmentation of some IGF-I effects after OT blockade, suggest that IGF-I action can be mediated by OT.
...
PMID:Oxytocin mediates some effects of insulin-like growth factor-I on porcine ovarian follicles. 1496 39
The aim of our in vitro experiments was to study the role of
oxytocin
(OT), cAMP/protein kinase A (PKA), and
mitogen-activated protein kinase
(ERKs MAP-kinase) in the control of ovarian cell functions as well as the role of PKA and
MAPK
in mediating OT effects on these processes. The whole porcine ovarian follicles were cultured in the presence or absence of OT (1, 10, 100 ng/ml), PKA inhibitor Rp-cAMPS (10 nM), MAP-kinase inhibitor PD98059 (1 microg/ml), or their combination. The release of prostaglandins F (PGF) and E (PGE) were determined by RIA, PKA (alpha-cat subunit), the proliferation-associated peptide PCNA and ERK-1, -2 expression in cell lyzates were analysed by Western-blotting. OT stimulated the release of PGF and PGE, and accumulation of PKA, ERK-1/-2, and PCNA in cell lysate. PD98059 decreased the basal PGF and PGE output, as well as reduced both ERK-1 and ERK-2 accumulation in cell lysates. Rp-cAMPS decreased PKA accumulation in cell lysates. Rp-cAMPS prevented the OT-induced stimulation of PKA, ERK-1, ERK-2, PGF, and PGE, PD98059 did so for PKA, PGF, and PGE. However, PD98059 reduced either basal or OT-induced p-ERK level. OT-stimulated PCNA accumulation was only slightly modified by these blockers. These observations suggest that OT, PKA, and ERKs
MAPK
can be involved in the control of PGs release and proliferation of ovarian cells. The influence of OT on both PKA and
MAPK
, and the ability of PKA and
MAPK
blockers to prevent completely or partially OT effects suggest, that effects of OT on PGF and PGE can be mediated by both PKA and
MAPK
. The role of
MAPK
and PKA in mediating the proliferative effects of OT seems to be minor assuming the involvement of other intracellular messengers.
...
PMID:The role of oxytocin, protein kinase A, and ERK-related MAP-kinase in the control of porcine ovarian follicle functions. 1503 77
The hypothalamic nonapeptide
oxytocin
plays a crucial role in many reproductive and behavioural functions. However, in recent years, an additional new role for
oxytocin
has been identified in neoplastic pathology. In tumours,
oxytocin
acts as a growth regulator, through the activation of a specific G-coupled transmembrane receptor, the oxytocin receptor. In vitro,
oxytocin
inhibits proliferation of neoplastic cells of either epithelial (mammary and endometrial), nervous or bone origin, all expressing oxytocin receptor. Furthermore, an
oxytocin
growth-inhibiting effect was also tested and confirmed in vivo in mouse and rat mammary carcinomas. In neoplastic cells derived from two additional
oxytocin
target tissues, trophoblast and endothelium,
oxytocin
was found to promote cell proliferation, an effect opposite to that previously described in all other neoplastic
oxytocin
-responsive cells. The signal transduction pathways coupled to the biological effects of
oxytocin
are different in
oxytocin
growth-inhibited or growth-stimulated cells, and may depend on the membrane localization of the oxytocin receptor itself. The inhibitory effect of
oxytocin
is apparently mediated by activation of the cAMP-protein kinase A pathway, a nonconventional
oxytocin
signalling pathway, whereas the mitogenic effect is coupled to the increase of intracellular [Ca(2+)] and tyrosine phosphorylation, 'classical'
oxytocin
transducers. Moreover, the oxytocin receptor localization in lipid rafts enriched in caveolin-1 turns the inhibition of cell growth into a proliferative response, eliciting different epidermal growth factor receptor/
mitogen-activated protein kinase
activation patterns. This unexpected role of
oxytocin
(and
oxytocin
analogues) in regulating cell proliferation, as well as the widespread expression of
oxytocin
receptors in neoplastic tissues of different origin, opens up new perspectives on the biological role of the
oxytocin
-oxytocin receptor system in cancer.
...
PMID:Oxytocin and oxytocin receptors in cancer cells and proliferation. 1508 75
Malignant growth of small-cell lung carcinoma is promoted by various neuroendocrine autocrine/paracrine loops. Therefore, to interfere with this mitogenic process, it is crucial to elucidate the mechanisms involved. It is known that the
oxytocin
(OT) and vasopressin (VP) genes, normally transcriptionally restricted in their expression, are activated in small-cell lung cancer (SCLC), concomitantly with expression of their receptors (OTR, V1aR, V1bR/V3R and V2R). The aim of the present study was to characterize, in concentrations close to physiological and pharmacological conditions, intracellular signalling events triggered by OT and VP binding to their specific receptors in SCLC cells and to identify factors mediating OT- and VP-induced mitogenic effects on SCLC. Known agonists for OTR ([Thr4,Gly7]OT) and V1aR (F180), in addition to OT and VP, were able to elicit increases in cytosolic Ca2+ levels and this effect could be blocked using an OTR antagonist (OVTA) or a V1aR antagonist (SR49059) respectively. There was no activation of the cAMP pathway detected after VP, dDAVP (a V2R agonist), or OT treatment. Stimulation of SCLC cells with OT and VP led to an increase of
extracellular signal-regulated kinase
(
ERK
) 1/2 phosphorylation, maximal at 5 min, and the subsequent phosphorylation of its downstream target p90 ribosomal S6 kinase (p90RSK). Pre-incubation with OVTA and SR49059, and with inhibitors of phospholipase C (PLC), protein kinase C (PKC),
mitogen-activated protein kinase
/
ERK
kinase (MEK) 1/2 and a Ca2+ chelator significantly reduced OT- and VP-induced
ERK1
/2 phosphorylations. OVTA, SR49059 as well as MEK1/2 and PKC inhibitors also downregulated OT- and VP-induced p90RSK phosphorylation. In [3H]thymidine-uptake experiments, we subsequently observed that PLC, Ca2+, PKC and
ERK1
/2 are absolutely required for the OT- and VP-stimulated SCLC cellular growth process. In conclusion, the results presented here indicate that OT- and VP-induced mitogenic effects on SCLC are respectively mediated by OTR and V1aR signalling and that this mitogenic signalling passes through the phosphorylation of
ERK1
/2 and p90RSK in a PLC-, Ca2+-, PKC- and MEK1/2-dependent pathway.
...
PMID:Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. 1561 60
Tandospirone, an azapirone, is a selective serotonin(1A) (5-HT(1A)) receptor agonist. The effects of tandospirone on plasma hormones and on mitogen-activated protein (MAP) kinase activity in the brain of male rats were studied. Tandospirone produced a time- and dose-dependent increase in plasma levels of
oxytocin
, adrenocorticotropin (ACTH), corticosterone, and prolactin. The minimal dose of tandospirone that led to a significant elevation of plasma
oxytocin
, ACTH, and prolactin levels was 1.0 mg/kg (s.c.), while the minimal dose for corticosterone release was 3.0 mg/kg (s.c.). The ED(50) of tandospirone was 1.3 mg/kg for
oxytocin
, 1.2 mg/kg for ACTH, 3.0 mg/kg for corticosterone, and 0.24 mg/kg for prolactin. Pretreatment with the specific 5-HT(1A) receptor antagonist WAY 100,635 (0.3 mg/kg, s.c.) completely blocked the effects of tandospirone on plasma levels of
oxytocin
, ACTH, and corticosterone but shifted the dose-response curve for prolactin to the right. Tandospirone injection (10 mg/kg, s.c.) stimulated the
MAP kinase
signaling cascade, specifically the phosphorylation of p42/44
extracellular signal-regulated kinase
(
ERK
). Western blot analysis revealed a significant increase in phosphorylated
ERK
(p-ERK) levels in the hypothalamic paraventricular nucleus (PVN) as well as the dorsal raphe nucleus 5 min following tandospirone injection. These increases were blocked by pretreatment with WAY 100,635 (0.3 mg/kg). The results are the first evidence that systemic 5-HT(1A) receptor agonist administration produces a rapid increase in p-
ERK
levels in vivo, providing further insight into the signaling mechanisms of the 5-HT(1A) receptor.
...
PMID:Tandospirone activates neuroendocrine and ERK (MAP kinase) signaling pathways specifically through 5-HT1A receptor mechanisms in vivo. 1565 73
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>